HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Opinion Statement: Gastric and gastroesophageal junction (GEJ) cancers represent the third leading cause of malignancy-associated death worldwide. Approximately 15-20% of these adenocarcinomas overexpress the human epidermal growth factor receptor 2 (HER2), a pro-proliferative receptor tyrosine kina...
| Published in: | Current Treatment Options in Oncology Vol. 22; no. 10; pp. 1 - 17 |
|---|---|
| Main Authors: | , |
| Format: | research Journal Article |
| Published: |
Springer Nature
Oct2021
|
| Online Access: | View this record in EBSCOhost |